Recent changes in the management of primary HIV-1 infection: results from the French PRIMO cohort

HIV Medicine
V SchifferFrench PRIMO Cohort Study Group

Abstract

To describe the management of primary HIV infection (PHI), focusing on changes in the design of therapies and time to initiation of antiretroviral treatment, the clinical outcome, and the immuno-virological response over time to highly active antiretroviral therapy (HAART) and its tolerance. In the French PRIMO multicentre cohort, 291 patients presenting with PHI were enrolled between 1996 and 2001. Data were analysed to describe treatment prescription habits over a period of 5 years, and response to and tolerance of treatment. The proportion of patients who initiated treatment during PHI decreased from 92% in 1996 to 56% in 2001. At 6 months, whatever the initiated treatment, 74% of treated patients achieved a plasma viral load<400 HIV-1 RNA copies/mL and 53% achieved a viral load of<50 copies/mL. Prescription of protease inhibitor (PI)-sparing regimens has become more frequent since 1999. Despite a similar virological response, patients in the PI-containing group tended to experience a greater 1-year increase in CD4 cell count than those in the non-nucleoside reverse transcriptase (NNRTI)-containing group (218 cells/microL versus 157 cells/microL, respectively). An adverse event was recorded in 51% of treated patients. The mo...Continue Reading

References

Aug 17, 1995·The New England Journal of Medicine·S Kinloch-De LoësL Mathiesen
May 29, 1999·The New England Journal of Medicine·J LisziewiczF Lori
Mar 29, 2000·Proceedings of the National Academy of Sciences of the United States of America·A OxeniusR E Phillips
Apr 25, 2000·AIDS Research and Human Retroviruses·B N PhenixA D Badley
Jul 6, 2000·Annals of Internal Medicine·D L PatersonN Singh
Oct 12, 2000·Nature·E S RosenbergB D Walker
Mar 20, 2001·JAMA : the Journal of the American Medical Association·S StaszewskiUNKNOWN CNAAB3005 International Study Team
May 1, 2001·The American Journal of Psychiatry·J A Ciesla, J E Roberts
Jul 4, 2002·JAMA : the Journal of the American Medical Association·Patrick G YeniPaul A Volberding
Mar 6, 2003·Annals of Internal Medicine·Mark DybulUNKNOWN Panel on Clinical Practices for Treatment of HIV

❮ Previous
Next ❯

Citations

Aug 11, 2005·Current HIV/AIDS Reports·Malini Soogoor, Eric S Daar
Feb 25, 2005·Current Infectious Disease Reports·Malini Soogoor, Eric S Daar
Feb 1, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cécile GoujardUNKNOWN Agence Nationale de Recherche sur le Sida PRIMO Study Group
Jun 30, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Bruno HoenUNKNOWN QUEST Study Group
Jun 24, 2008·The Journal of Antimicrobial Chemotherapy·Inmaculada Jiménez-NácherVincent Soriano
Mar 14, 2012·PloS One·Nikos PantazisUNKNOWN CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group
Oct 11, 2008·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Remonie SengUNKNOWN ANRS PRIMO and SEROCO Study Groups
Aug 30, 2005·European Journal of Public Health·Rosemary Dray-SpiraUNKNOWN Primo Cohort Study Group
Sep 28, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Rosemary Dray-SpiraUNKNOWN PRIMO Cohort Study Group
Aug 13, 2011·Journal of the International AIDS Society·M Eugenia SocíasUNKNOWN Grupo Argentino de Seroconversión Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.